EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nilotinib revisited in GIST: salvage use in patients with severe imatinib toxicity

Johanna Falkenhorst iD, Peter Hohenberger iD, Giorgia Mancino, Andrea Scrima, Franka Menge, Benjamin S Fletcher, Carina Reiff, Valerie Lange, Rainer Hamacher, Stefanie Bertram, Fiona M Rau, Yasmin Zaun und 8 weitere

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Johanna Falkenhorst und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, 45122, Germany. Hauptthemen laut MEDLINE: Pyrimidines, Imatinib Mesylate, Gastrointestinal Stromal Tumors. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation, State of North Rhine-Westphalia (NRW), European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Severe imatinib toxicity is a rare, but relevant event in GIST patients. Other approved treatments were not evaluated within a first-line setting and exhibit severe adverse events that limit QoL. Nilotinib was evaluated within this setting in GIST with a safety profile comparable to imatinib and effectiveness within KIT-exon-11-mutant GIST subgroup (ENESTg1). Materials, patients, and methods This is a retrospective case series reporting the outcome and side effects of 20 patients treated with nilotinib following severe imatinib toxicity. Nilotinib efficacy was tested in GIST cell lines carrying common primary and resistance mutations in KIT. Inhibitory profile of nilotinib was characterized using in silico modeling.

Results

In our retrospective analysis of 1263 patients, 7.3% of patients discontinued imatinib due to toxicity. In 20 patients who received nilotinib, reasons were skin (n = 11) and liver (n = 4) toxicity, followed by cardiac (n = 2) and gastrointestinal toxicities (n = 2). No cross-toxicities were observed with nilotinib treatment. Nilotinib was effective after imatinib intolerance. A secondary KIT Exon 9 mutation was found in a progressing lesion. In vitro viability assays showed effectiveness in KIT-Exon-11-mutant cell lines, but not in Exon 9 or imatinib-resistant mutations in doses deemed clinically achievable. In silico modeling revealed steric hindrance by Exon 9 or imatinib resistance mutations.

Conclusion

Nilotinib exhibits no cross toxicity with imatinib and represents an important alternative in imatinib-sensitive, KIT-exon-11-mutant GIST given its excellent toxicity profile. There is no biological rationale for the use of nilotinib in imatinib-resistant GIST with secondary KIT mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesImatinib MesylateGastrointestinal Stromal TumorsHumansFemaleMiddle AgedMaleSalvage TherapyAgedMutationAdultRetrospective StudiesProto-Oncogene Proteins c-kitDrug Resistance, NeoplasmAntineoplastic AgentsProtein Kinase Inhibitors

Stichwörter der Autor:innen

GISTimatinib toxicitynilotinibresistancesalvage treatment

Substanzen

nilotinibPyrimidinesImatinib MesylateProto-Oncogene Proteins c-kitAntineoplastic AgentsKIT protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, 45122, Germany.
  • DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, 69120, Germany.
  • National Center for Tumor Diseases (NCT) West, Essen, 45122, Germany.
  • Division of Surgical Oncology, Medical Faculty Mannheim of University of Heidelberg.
  • Department of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, 44227, Germany.
  • Drug Discovery Hub Dortmund (DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), Dortmund, 44227,Germany.

ORCID-Profile: Johanna Falkenhorst, Peter Hohenberger, Daniel Rauh, Sebastian Bauer

Förderung

  • German Research Foundation
  • State of North Rhine-Westphalia (NRW)
  • European Union
  • German Federal Ministry of Education and Research
  • Mercator Research Center Ruhr (MERCUR)
  • IGNITE
  • Ministry of Culture and Science of the State of North Rhine-Westphalia
  • Targeting Transcriptional Addiction in Cancer (TACTIC)

Zitieren

APA

Falkenhorst, J., Hohenberger, P., Mancino, G., Scrima, A., Menge, F., Fletcher, B. S., Reiff, C., Lange, V., Hamacher, R., Bertram, S., Rau, F. M., Zaun, Y., Kaths, M., Treckmann, J., Jakob, J., Mühlenberg, T., Grunewald, S., Krzeciesa, D., Rauh, D., & Bauer, S. (2026). Nilotinib revisited in GIST: salvage use in patients with severe imatinib toxicity. The Oncologist. https://doi.org/10.1093/oncolo/oyag345

Vancouver

Falkenhorst J, Hohenberger P, Mancino G, Scrima A, Menge F, Fletcher BS, et al. Nilotinib revisited in GIST: salvage use in patients with severe imatinib toxicity. The Oncologist. 2026. doi:10.1093/oncolo/oyag345

BibTeX
@article{Falkenhorst2026,
  author = {Falkenhorst, Johanna and Hohenberger, Peter and Mancino, Giorgia and Scrima, Andrea and Menge, Franka and Fletcher, Benjamin S and Reiff, Carina and Lange, Valerie and Hamacher, Rainer and Bertram, Stefanie and Rau, Fiona M and Zaun, Yasmin and Kaths, Moritz and Treckmann, Jürgen and Jakob, Jens and Mühlenberg, Thomas and Grunewald, Susanne and Krzeciesa, Dawid and Rauh, Daniel and Bauer, Sebastian},
  title = {Nilotinib revisited in GIST: salvage use in patients with severe imatinib toxicity},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag345}
}
Kostenlos starten →